Related Experiment Video

Updated: Jul 1, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K

Comparative Efficacy of Curative Effects of Sacubitril/Valsartan in HFpEF versus HFrEF Treatment

Yi Li, Zifan Zhu, Hongbin Liu

    Alternative Therapies in Health and Medicine
    |March 2, 2024
    PubMed

    Insights

    Sacubitril/Valsartan improved renal function and quality of life in heart failure with preserved ejection fraction (HFpEF) patients more than in those with reduced ejection fraction (HFrEF). Both groups showed similar survival benefits from this heart failure medication.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Heart failure is a complex syndrome with subtypes based on ejection fraction.
    • Sacubitril/Valsartan is a key medication for heart failure management.

    Purpose of the Study:

    • To compare the efficacy of Sacubitril/Valsartan in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
    • To guide heart failure medication strategies based on ejection fraction.

    Main Methods:

    • Retrospective cohort study of 89 patients (48 HFrEF, 41 HFpEF) treated with Sacubitril/Valsartan.
    • Assessed cardiac and renal function, mobility (6-minute walk test), quality of life (MLHFQ), readmission, and survival rates over one year.

    Main Results:

    • No significant difference in adverse reactions or cardiac function changes between HFrEF and HFpEF groups.
    • HFpEF patients showed greater improvements in renal function (serum creatinine, BUN) and quality of life metrics (6MWT, MLHFQ) compared to HFrEF patients.
    • HFpEF group had a lower readmission rate, but survival rates were comparable between groups.

    Conclusions:

    • Sacubitril/Valsartan offers superior renal and quality-of-life benefits in HFpEF patients.
    • The medication provides comparable prognostic benefits for both HFrEF and HFpEF patients.
    • Sacubitril/Valsartan is a valuable therapeutic option across different heart failure ejection fraction categories.
    Abstract

    More Related Videos

    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

    Published on: February 18, 2022

    1.9K
    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

    Published on: December 11, 2017

    10.5K

    Related Concept Videos

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    429
    Dose-Response Relationship: Potency and Efficacy01:22

    Dose-Response Relationship: Potency and Efficacy

    The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
    4.4K
    Pathophysiology of Heart Failure01:17

    Pathophysiology of Heart Failure

    Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
    1.6K
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    375
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
    165
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
    338